Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials*
The DOI matches its Crossref record, with a small difference in title or year; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Venous thromboembolism prevention during critical illness is a widely used quality metric. The objective of this systematic review was to systematically review the efficacy and safety of heparin thromboprophylaxis in medical-surgical patients in the ICU. DATA SOURCES: We searched EMBASE, MEDLINE, the Cochrane Controlled Trials Register, Clinicaltrials.gov, and personal files through May 2012. STUDY SELECTION: Randomized trials in adult medical-surgical ICU patients comparing any heparin (unfractionated heparin or low-molecular-weight heparin) with each other or no anticoagulant prophylaxis, evaluating deep vein thrombosis, pulmonary embolism, major bleeding, or mortality. DATA EXTRACTION: Independently, in duplicate, we abstracted trial characteristics, outcomes, and risk of bias. DATA SYNTHESIS: Seven trials involved 7,226 patients. Any heparin thromboprophylaxis compared with placebo reduced rates of deep vein thrombosis (pooled risk ratio, 0.51 [95% CI, 0.41, 0.63]; p<0.0001; I=77%) and pulmonary embolism (risk ratio, 0.52 [95% CI, 0.28, 0.97]; p=0.04; I=0%) but not symptomatic deep vein thrombosis (risk ratio, 0.86 [95% CI, 0.59, 1.25]; p=0.43). Major bleeding (risk ratio, 0.82 [95% CI, 0.56, 1.21]; p=0.32; I=50%) and mortality (risk ratio, 0.89 [95% CI, 0.78, 1.02]; p=0.09; I=0%) rates were similar. Compared with unfractionated heparin, low-molecular-weight heparin reduced rates of pulmonary embolism (risk ratio, 0.62 [95% CI, 0.39, 1.00]; p=0.05; I=53%) and symptomatic pulmonary embolism (risk ratio, 0.58 [95% CI, 0.34, 0.97]; p=0.04) but not deep vein thrombosis (risk ratio, 0.90 [95% CI, 0.74, 1.08]; p=0.26; I=0%), symptomatic deep vein thrombosis (risk ratio, 0.87 [95% CI, 0.60, 1.25]; p=0.44; I=0%), major bleeding (risk ratio, 0.97 [95% CI, 0.75, 1.26]; p=0.83; I=0%), or mortality (risk ratio, 0.93 [95% CI, 0.82, 1.04]; p=0.20; I=31%). CONCLUSIONS: Trial evidence to date suggests that any type of heparin thromboprophylaxis decreases deep vein thrombosis and pulmonary embolism in medical-surgical critically ill patients, and low-molecular-weight heparin compared with bid unfractionated heparin decreases pulmonary embolism and symptomatic pulmonary embolism. Major bleeding and mortality rates do not appear to be significantly influenced by heparin thromboprophylaxis in the ICU setting. Trial methodology, indirectness, and the heterogeneity and imprecision of some results temper inferences from this literature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The incidence of DVT acquired in the ICU may be as high as 10% [497], the incidence of acquired PE may be 2–4% [498, 499].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [498]
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Mismetti, P., Laporte, S., Darmon, J.-Y., Buchmüller, A., & Decousus, H. (2001) · Journal of British Surgery · doi:10.1046/j.0007-1323.2001.01800.x · Cited by 649 · cited 4×
“These results complement estimates from trials in general medical patients (1, 2) and surgical populations (3, 42) yielding similar findings.”
BackgroundResultInfluentialDeep Vein Thrombosis and Its Prevention in Critically Ill Adults
Attia, J., Ray, J. G., Cook, D. J., Douketis, J., Ginsberg, J. S., & Geerts, W. H. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.10.1268 · Cited by 617 · cited 9×
“If the natural history of VTE in critically ill patients parallels that in other patients, the prevalence of PE in this review is likely to be conservative, because trial patients in whom DVT might develop are typically therapeutically anticoagulated, thereby lowering the risk of thrombus propagation, embolization, an…”
BackgroundInfluentialSelf-citationInterstitial Lung Disease: A Quantitative Study Using the Adaptive Multiple Feature Method
UPPALURI, R., HOFFMAN, E. A., SONKA, M., HUNNINGHAKE, G. W., & McLENNAN, G. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.2.9707145 · Cited by 564
Dentali, F., Douketis, J. D., Gianni, M., Lim, W., & Crowther, M. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-4-200702200-00007 · Cited by 544 · cited 4×
“These results complement estimates from trials in general medical patients (1, 2) and surgical populations (3, 42) yielding similar findings.”
BackgroundResultInfluentialSelf-citation(2009) · The Lancet · doi:10.1016/s0140-6736(09)60941-7 · Cited by 481 · cited 1×
“However, the effect of antiembolic stockings has been called into question by the Clots in Legs Or sTockings after Stroke (CLOTS)-1 (40) and CLOTS-2 (41) trials, and pneumatic compression devices have not been tested in trials in this population.”
BackgroundDalteparin versus Unfractionated Heparin in Critically Ill Patients
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014475 · Cited by 459
Pogue, J. M., & Yusuf, S. (1997) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00051-2 · Cited by 415 · cited 1×
“parisons exceeds the threshold of the optimal information size (39), we conservatively downgraded the quality of evidence for some endpoints with very few events due to imprecision.”
BackgroundPrevalence of Deep Venous Thrombosis Among Patients in Medical Intensive Care
Hirsch, D. R. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530040063042 · Cited by 318 · cited 3×
“Symptomatic DVT 2 (4,722) Intervention, 51/2,351 (2.”
Background
Research works printed but not linked: 1
- Goldhaber, 2000, J Am Coll Cardiol, 35, 325A
Cited by
Items 101–170 of 170
Acquired Coagulopathy and Hemorrhage Secondary to Subcutaneous Heparin Prophylaxis
Sunseri, M. W., Ahuja, T., Wilcox, T., & Green, D. (2018) · Case Reports in Hematology · doi:10.1155/2018/9501863 · Cited by 5
Samuel, S., To, C., Ling, Y., Zhang, K., Jiang, X., & Bernstam, E. V. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-022-02755-w · Cited by 5
“This study reflects real-world experience and diverse population with respect to race as most previous studies included mainly white patients [5, 8].”
ResultExfoliative Diseases of the Integument and Soft Tissue Necrotizing Infections
Fagan, S. P., Carson, J. S., Jimenez, C., Chai, J., Spies, M., Hollyoak, M. A., Müller, M. J., Goodwin, C. W., & Herndon, D. N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-47661-4.00042-3 · Cited by 5
Arias-Amézquita, F., Herrera‐Almario, G., Pozo, M. E., Londoño-Schimmer, E., Otero, J. M., Cardona, A. F., Cortés, N., & Mora, M. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4064-0 · Cited by 4
Anticoagulación en pacientes con infección por COVID-19
Pájaro-Galvis, N., Abuabara-Franco, E., Martínez, V. L., Serpa-Díaz, D., Rico-Fontalvo, J. E., Daza-Arnedo, R., Bohórquez-Rivero, J., Correa-Guerrero, J., Fontalvo, J. L., Pomares-Lara, A., et al. (2020) · Salud UIS · doi:10.18273/revsal.v52n4-2020009 · Cited by 4
“Wu, et al (2020) n:117 (2) 1,16 (0,46-5,37) 187,00 (124,50-252,50) 11,70 (11,10-12,45)”
Mittman, B. G., Hu, B., Schulte, R., Le, P., Pappas, M. A., Hamilton, A. C., & Rothberg, M. B. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.02.004 · Cited by 3
“Randomized controlled trials in medical inpatients have demonstrated that prophylaxis with low-molecular-weight heparin (LMWH) can reduce symptomatic VTE [5–8].”
Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
Gurjar, M. (2014) · Indian Journal of Critical Care Medicine · doi:10.4103/0972-5229.133867 · Cited by 3
“, did systematic review and meta-analysis of seven RCTs of heparin (unfractionated heparin (UFH) or low-molecular -weight hepar in (LMWH)) thromboprophylaxis in medical-surgical critically ill patients, with exclusion criteria of pediatric, trauma, neurosurgery or cardiac surgery population.[5] In this meta-analysis,…”
Utilización de medidas de tromboprofilaxis en niños críticamente enfermos en España y Portugal
Rodríguez‐Núñez, A., Fonte, M., & Faustino, E. V. S. (2014) · Anales de Pediatría · doi:10.1016/j.anpedi.2014.05.001 · Cited by 3
“Historia previa de trombosis 17 (5,5) 100 (4,6)) 0,47”
BackgroundInfluentialAngel® Catheter — A Solution to Pulmonary Embolism Prophylaxis in the Critically Ill Patient
Angel, L. F. (2014) · Journal of the Intensive Care Society · doi:10.1177/17511437140151s304 · Cited by 3
Sengodan, P. M., Sankaramangalam, K. P., Li, M., Wang, X., Subramaniam, S., & Alappan, N. (2019) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2019.01.061 · Cited by 3
Venous Thromboembolism Prophylaxis in Intensive Care Units (Review)
Popova, L. V., Борисовна, К. Т., Kanevskaya, M., Aleinikova, T. L., Zykova, E. S., Krivova, A. V., & Kuznetsov, A. M. (2020) · General Reanimatology · doi:10.15360/1813-9779-2020-3-106-125 · Cited by 3
“The findings of five studies were evaluated by the authors of clinical recommendations of the American College of Chest Physicians (CHEST) in 2012 [46], and in 2013 a meta-analysis of seven RCS was published [73].”
La profilaxis de la enfermedad tromboembólica venosa en los pacientes con enfermedad médica
Criado-García, J. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.07.005 · Cited by 3
Intensive Care Society State of the Art 2016 Abstracts
Auzinger, G., Best, T., Gelandt, E., Hurst, T., Kakar, V., Loveridge, R., Morgan, L., Nevett, J., Park, C., Patel, S., et al. (2016) · Journal of the Intensive Care Society · doi:10.1177/1751143717708966 · Cited by 4
Haas, L. E. M., de Lange, D. W., & Martín‐Loeches, I. (2022) · Lessons from the ICU · doi:10.1007/978-3-030-94133-8_30 · Cited by 4
Mer, M., Schultz, M. J., Adhikari, N. K. J., Kwizera, A., Mohanty, S., Dondorp, A. M., Neto, A. S., & Preller, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-03143-5_5 · Cited by 4
Illustrated State‐of‐the‐Art Capsules of the ISTH 2020 Congress
Ariëns, R. A. S., Becattini, C., Bender, M., Bergmeier, W., Castoldi, E., Devreese, K. M. J., Ellis, M. H., Gailani, D., Ignjatović, V., James, A., et al. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12368 · Cited by 3
Observational vs randomized: David vs Goliath for thromboprophylaxis in critically ill patients?
Helms, J., Bion, J., & JONG, A. D. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05541-0 · Cited by 3
Vandenbriele, C., der Linden, L. R. V., Vanassche, T., & Verhamme, P. B. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.05.31 · Cited by 3
“Although pharmacologic thromboprophylaxis reduced the incidence of deep-vein thrombosis by 50% compared with no prophylaxis in critically ill patients, still 5% to 20% of this pharmacologically treated patient group develops deep-vein thrombosis (6,9,10).”
BackgroundJara‐Palomares, L., Marín-Romero, S., Asensio-Cruz, M. I., Elías-Hernández, T., & Otero, R. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.05.38 · Cited by 3
“Pharmacologic thromboprophylaxis with low molecular weight heparin (LMWH) or unfractionated heparin (UFH), in trials, have shown a reduction of the incidence of DVT nearly 50% (2).”
BackgroundAlana, N. B., Ciurylo, W. A., & Hurlock, N. P. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02910-x · Cited by 2
“These findings may underlie what has been found in pre - vious studies recommending enoxaparin as superior to heparin for venous thromboembolism prophylaxis in sepsis critically ill medical inpatients [41 ].”
Illustrated State‐of‐the‐Art Capsules of the ISTH 2021 Congress
Krishnaswamy, S., Ageno, W., Arabi, Y. M., Barbui, T., Cannegieter, S. C., Carrier, M., Cleuren, A. C. A., Collins, P. W., Panicot‐Dubois, L., Freedman, J. E., et al. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12532 · Cited by 2
“63).(4) Data on the effectiveness of pneumatic review that included observational studies demonstrated lower DVT with intermittent pneumatic compression (RR 0.”
BackgroundDeep Vein Thrombosis in Intensive Care
Boddi, M., & Peris, A. (2015) · Advances in experimental medicine and biology · doi:10.1007/13780_2015_2 · Cited by 2
The Landscape of Thromboprophylaxis Utilization in Critically ill Children
Gist, K. M., & Chima, R. S. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000185 · Cited by 2
Dabbagh, A., Mielke, J., Mühlberg, K. S., Hoffmann, K., Lindner, D., Huber, C., Michalski, D., & Pelz, J. O. (2025) · Stroke and Vascular Neurology · doi:10.1136/svn-2024-003808 · Cited by 1
“AD and JM collected the data and conducted the analysis.”
Management of Critically Ill Head and Neck Surgical Patients
Nayyar, V. (2015) · Head and neck cancer clinics · doi:10.1007/978-81-322-2497-6_12 · Cited by 1
Critical Care Prophylaxis. Sometimes Less Is More
Lewis, K. A., Spence, J. D., Dionne, J. C., & Rochwerg, B. N. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201904-0821rr · Cited by 1
Östlund, Å., Fläring, U., Larsson, P., Kaiser, S., Vermin, L., Frisk, T., Dahlberg, A., Berner, J., Norberg, Å., & Andersson, A. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-022-04487-8 · Cited by 1
“In adult ICU patients, there is a 50% lower risk of VTE with the use of heparins for VTE prophylaxis [9], but no data from the paediatric setting exist.”
BackgroundShields, L. E., Feldman, D. S., Klein, C., Foster, M., & Lin, S. N. (2024) · American Journal of Perinatology · doi:10.1055/a-2342-0919 · Cited by 1
Arunothai, S., Sutherasan, Y., Panpikoon, T., Theerawit, P., Angchaisuksiri, P., & Boonyawat, K. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102522 · Cited by 1
“Several studies have shown that the use of heparin or low-molecular-weight heparin is associated with a lower risk of DVT in ICU patients [7].”
BackgroundThe journey to zero deep-vein thrombosis in critically ill patients
Arabi, Y. M., Alsolamy, S. J., & Al‐Dawood, A. (2019) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_179_19 · Cited by 1
“[15] A systematic review of heparin (unfractionated and low‐molecular‐weight heparin) versus placebo showed that heparin reduces DVT by around 50% and PE by 50%.[16] These data not only document the benefit of heparin in DVT prevention, but also demonstrate a substantial residual risk even when heparin is administered.”
Heparin Anticoagulation for Hospitalized Patients with COVID-19
Carlin, S., Morris, A. M., Abdurrahman, Z. B., Bailey, J. J., Betts, M., Ciccotelli, W. A., Langford, B. J., Leung, E., Maltsev, A., Munshi, L., et al. (2021) · doi:10.47326/ocsat.2021.02.41.1.0 · Cited by 1
To Generalize or Not to Generalize?
McMahon, M. M. J., & Holley, C. A. B. (2022) · CHEST Journal · doi:10.1016/j.chest.2021.09.017 · Cited by 1
Prevention of Venous Thromboembolism
Dittus, C. E., Sarosiek, S., & Ansell, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-30352-9_38 · Cited by 1
Thromboprophylaxis in critically ill children in Spain and Portugal
Rodríguez‐Núñez, A., Fonte, M., & Faustino, E. V. S. (2015) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2014.05.002
Volpi, N. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31828fd852
Implementing implementation science
Manthous, C. A. (2014) · Journal of Critical Care · doi:10.1016/j.jcrc.2014.01.008
“A just published meta-analysis [5] helps us judge the validity of this assumption.”
BackgroundThromboprophylaxis in Patients with Abdominal Sepsis
Coccolini, F., Catena, F., Montori, G., Ceresoli, M., Fugazzola, P., Tomasoni, M., Corbella, D., Sartelli, M., & Ansaloni, L. (2017) · Hot topics in acute care surgery and trauma · doi:10.1007/978-3-319-59704-1_25
Prophylaxis of Venous Thromboembolism in Home Care: An Integrative Review
Marrochi, L. C. R. (2017) · Home Healthcare Now · doi:10.1097/nhh.0000000000000534
Clinical Pharmacokinetic Analysis and Modeling of Tranexamic Acid in Dogs
Almoslem, M. (2018)
Additive Therapien: Intensivmedizinische Studien aus 2018/2019
Dietrich, M., Reuß, C. J., Beynon, C., Hecker, A., Jungk, C., Michalski, D., Nußhag, C., Schmidt, K., Weigand, M. A., Bernhard, M. H., et al. (2019) · Der Anaesthesist · doi:10.1007/s00101-019-00642-3
The modern concept of intensive therapy of coagulopathy, which is complicate polytrauma and shock
Cherniy, V. I. (2019) · Clinical and Preventive Medicine · doi:10.31612/2616-4868.2(8).2019.01
What anticoagulants should be used in the critically ill patient? How do I choose?
Hendrix, C. J., Rivas, L., & Sarani, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-64068-8.00092-4
What happens to the autonomic nervous system in critical illness?
Ackland, G. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-64068-8.00049-3
R.Rambaran, & D.Ventour (2021) · Journal of Perioperative Medicine · doi:10.35248/2684-1290.21.4.110
Venous Thromboembolism in COVID 19 Infection: Prevalence and Practice of Prophylaxis - A Narrative
Rao, U. V., & Wasim, M. (2021) · Indian Journal of Vascular and Endovascular Surgery · doi:10.4103/ijves.ijves_97_20
Venous Thromboembolic Disease: DVT and PE
Marik, P. E. (2014) · Springer eBooks · doi:10.1007/978-3-319-11020-2_27
Kaur, J., deLongpre, J., Koehler, T., Laclair, H., Bowen, M., Khine, J., Khosrodad, N., Jena, N. K., Dixit, P., Yadav, S., et al. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001462
Tambo, W., Aronowitz, D. I., Sisa, I., Diaz, E., Lee, A. Y., Cagliani, J. A., Torres, F. J., & Barrera, R. (2022) · Cureus · doi:10.7759/cureus.24324
Dellinger, R. P., & Jaeschke, R. (2013) · Critical Care Medicine · doi:10.1097/ccm.0000000000000055
Self-citation30/m mit postoperativer Dyspnoe und Thoraxschmerzen
Rupprecht, B., & Rach, P. R. (2022) · Die Anaesthesiologie · doi:10.1007/s00101-022-01163-2
“G. Breuer, Coburg A. Heller, Augsburg M. Sander, Gießen 30/mmit postoperativer Dyspnoe und Thoraxschmerzen Vorbereitungskurs Anästhesiologische Intensivmedizin: Fall 11 Bernd Rupprecht · Patric Rach Klinik für Anästhesiologie und Operative Intensivmedizin, UniversitätsklinikumAugsburg, Augsburg, Deutschland Prüfungssi…”
BackgroundProphylaxe venöser Thromboembolien in der nicht-operativen Medizin
Haas, S. K., & Linnemann, B. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-61379-5_118-1
Sulaiman, K. A. A., Alshehri, A., Vishwakarma, R. K., Bakhsh, U., Kharbosh, A., Mokali, A., & Aljuhani, O. A. (2022) · Saudi Journal of Clinical Pharmacy · doi:10.4103/sjcp.sjcp_1_21
Bingold, T. M., Hoffmann, M. W. G., Krotsetis, S., & Muhl, E. (2023) · Springer Reference Medizin · doi:10.1007/978-3-642-54675-4_43-2
Pérez-Fernández, J., & Perez, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88271-2.00029-8
Prophylaxe venöser Thromboembolien in der nicht-operativen Medizin
Haas, S. K., & Linnemann, B. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-61379-5_118-2
Amin, A., Kartashov, A. I., Ngai, W., Steele, K., & Rosenthal, N. A. (2024) · Journal of health economics and outcomes research · doi:10.36469/001c.92408 · Cited by 1
Bingold, T. M., Hoffmann, M. W. G., Krotsetis, S., & Muhl, E. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-68699-7_43
Văn, B. N., & Duy, K. N. (2025) · Tạp chí Y học Việt Nam · doi:10.51298/vmj.v551i1.14461
Tang, X., Lyu, W.-R., Jin, Y., Wang, R., Li, X.-Y., Li, Y., Zhang, C.-Y., Zhao, W., Tong, Z.-H., & Sun, B. (2023) · Figshare · doi:10.6084/m9.figshare.22606696
Prophylaxe venöser Thromboembolien in der nicht-operativen Medizin
Haas, S. K., & Linnemann, B. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-60880-7_118
Alruwaili Maryam Ayed, A., Alanazi Abdulrahman Lafi, O., Aljoufi, G. A. G., Alanazi, I. F. F., Alahmari Abdullah Ali, A., Almutairi, M. K., Alshamlani Maitha Qibi, K., Alanazi, A. A. B., Alruwaili, M. A., Nagmosh, A. A. M., et al. (2024) · International Journal of Computational and Experimental Science and Engineering · doi:10.22399/ijcesen.4616
“Epidemiological studies consistently highlight VTE as a leading cause of preventable hospital death, with incidence rates remaining persistently high despite advances in medical knowledge and prophylactic strategies [2].”
Buensalido, J. A. L., Malundo, A. F. G., Aherrera, J. A. M., Magno, J. D. A., Maramara, M. K. P., Punzalan, F. E. R., Tolosa, M. T. S., Briones, G., Hernandez, A. M. R., Pantaleon, A. F., et al. (2022) · Philippine Journal of Internal Medicine · doi:10.65564/pjim.10a45be121
Estimated impact of model‐guided venous thromboembolism prophylaxis versus real‐world practice
Mittman, B. G., & Rothberg, M. B. (2026) · Journal of Hospital Medicine · doi:10.1002/jhm.70267
Pediatric hospital-acquired thrombosis: time for a CHAT
Monagle, P. (2026) · Blood · doi:10.1182/blood.2025032330
Sabry, S., Warda, A. E. A., Magdoub, H. M. E., EL‐Farook, D. H., Allah, N. S., Gaber, S., Ammar, M. K., & Abouelkheir, M. M. (2026) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-026-00961-4
Critical care in the severely burned: Organ support and management of complications
Culnan, D. M., Sherman, W. C., Chung, K. K., Sjöberg, F., & Wolf, S. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-88389-4.00035-x
A short history of anticoagulant therapy
Chan, N., Imiela, A. M., Carlin, S., & Hirsh, J. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109753
Pulmonary Embolism in Older Patients
Talati, T., Pisani, M. A., & Mathur, A. (2026) · Respiratory medicine · doi:10.1007/978-3-032-29861-4_10
Xue, Z., Guo, R., 娄孝林, Tian, Y., Tong, J., & Zhao, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1886512
Burad, J., Asati, N., Padmalayan, A., Kindi, R. H. Z. A., Yahyai, R. M. A., & Hashim, A. H. A. (2026) · Cureus · doi:10.7759/cureus.119373
Metadata
- Authors
- Alhazzani, W., Lim, W., Jaeschke, R. Z., Murad, M. H., Cade, J., & Cook, D. J.
- Affiliations
- McMaster University (CA)
- Mayo Clinic (US)
- The Royal Melbourne Hospital (AU)
- Venue
- Critical Care Medicine
- Published
- 2013-09
- Volume
- 41
- Issue
- 9
- Pages
- 2088-2098
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2321905524
- Semantic Scholar
- f75126a5fd7772a2752c0acc656c0010d7a06dc7
- Cited by
- 168
- References
- 29
- Citations by year
- 2026: 9 · 2025: 3 · 2024: 10 · 2023: 11 · 2022: 19 · 2021: 15 · 2020: 23 · 2019: 19 · 2018: 8 · 2017: 9 · 2016: 10 · 2015: 13 · 2014: 16 · 2013: 3
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Keywords
- thromboprophylaxis, deep vein thrombosis, pulmonary embolism, low molecular weight heparin, unfractionated heparin, major bleeding, mortality, intensive care unit patients, symptomatic pulmonary embolism, quality metrics, risk of bias
- MeSH terms
- Anticoagulants, Heparin, Low-Molecular-Weight, Hospitalization, Humans, Intensive Care Units, Randomized Controlled Trials as Topic, Critical Illness, Treatment Outcome, Venous Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.